Investor Relations

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 3, 2026-- Twist Bioscience Corporation (NASDAQ: TWST):

UNITED STATES DISTRICT COURT
DISTRICT OF DELAWARE

SUMMARY NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION

TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF TWIST BIOSCIENCE CORPORATION (“TWIST” OR THE “COMPANY”) COMMON STOCK AS OF OCTOBER 15, 2026 (THE “RECORD DATE”).

IF YOU WERE A RECORD OR BENEFICIAL OWNER OF TWIST COMMON STOCK AS OF THE RECORD DATE, PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY AS YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN THE ABOVE-REFERENCED LITIGATION.

PLEASE TAKE NOTICE that the above-captioned consolidated derivative action is being settled on the terms set forth in a Stipulation and Agreement of Settlement dated October 15, 2026 (the “Stipulation”),¹ subject to the approval of the United States District Court for the District of Delaware (the “Court”) pursuant to Rule 23.1 of the Federal Rules of Civil Procedure. Under the terms of the Stipulation, as part of the proposed Settlement, and in consideration of the associated releases set forth herein, Defendants shall cause the Board, within forty-five (45) days after the Court enters an Order granting final approval of the Settlement, to adopt, implement, and maintain the corporate governance reforms set forth in Exhibit A to the Stipulation, consistent with the terms and timing set forth therein (the “Reforms”). The Reforms, which are detailed more fully in the Stipulation and Long Form Notice, are intended to address the claims asserted in the Derivative Action.

The Parties agree that: (1) the Settlement confers a substantial benefit upon Twist and its shareholders; (2) the Settlement, and each of its terms, is in all respects fair, adequate, reasonable, and in the best interests of Twist and its shareholders; and (3) Plaintiffs’ Counsel shall be paid reasonable attorneys’ fees and reimbursement of expenses, inclusive of Service Awards for the Plaintiffs, subject to the approval of the Court.

On January 22, 2027, at 10:00 a.m., the Court will hold the Settlement Hearing in Courtroom 4A at the United States District Court for the District of Delaware, 844 N. King Street, Wilmington, Delaware 19801-3555. At the Settlement Hearing, the Court will consider whether the Settlement is fair, reasonable, and adequate and thus should be finally approved and whether the above-captioned consolidated derivative action should be dismissed with prejudice pursuant to the Stipulation. The Court also will rule upon Plaintiffs’ Counsel’s request for approval of the agreed-to attorneys’ fees and reimbursement of expenses and Plaintiffs’ Service Awards.

Any Current Twist Stockholder may, but is not required to, appear at the Settlement Hearing. If you want to be heard at the Settlement Hearing in opposition to the Settlement, Plaintiffs’ Counsel’s request for approval of attorneys’ fees and reimbursement of expenses, or the Service Awards, then you must first comply with the following procedures for objecting.

Any objections to the proposed Settlement or Plaintiffs’ Counsel’s applications for the Fee and Expense Amount of $1,000,000, to be paid by the Individual Defendants’ Insurers, and reasonable Service Awards of up to $2,000 for each of the two Plaintiffs to be paid from the Fee and Expense Amount, must be presented in writing and must contain the following information:

1. Notice of intent to appear at the Settlement Hearing;
2. Your name, legal address, and telephone number;
3. Proof of being a Current Twist Stockholder as of the Record Date and representation that you will continue to own Twist common stock as of the date of the Settlement Hearing;
4. The date(s) which you acquired your Twist shares and the number of Twist shares held;
5. A detailed statement of your specific position with respect to the matters to be heard at the Settlement Hearing, including a statement of each objection being made; and
6. The grounds for each objection or the reasons for your desire to appear and be heard.

Any counsel retained by a putative objector for the purpose of asserting an objection must make a notice of appearance on the Court at least fourteen (14) days before the Settlement Hearing. The Court may not consider any objection that does not substantially comply with these requirements.

Any written objections must be filed with the Court and sent by hand or by first class mail, postage pre-paid to Plaintiffs’ Counsel and Defendants’ Counsel no later than fourteen (14) days prior to the Settlement Hearing at the following address:

The Court may not consider any objection that is not timely filed with the Court and delivered to Plaintiffs’ Counsel and Defendants’ Counsel.

Any person or entity who fails to object or otherwise requests to be heard in the manner prescribed above will be deemed to have waived the right to object to any aspect of the Settlement, will be deemed to have waived any request to be heard (including the right to appeal), and will be forever barred from raising such objection or request to be heard in this or any other action or proceeding, but shall otherwise be bound by the Judgment to be entered and the releases to be given.

This Notice summarizes the Parties’ Stipulation. It is not a complete statement of the events of the Derivative Action or the Stipulation. You may inspect the Stipulation and other papers at https://investors.twistbioscience.com/.

PLEASE DO NOT CALL, WRITE, OR OTHERWISE DIRECT QUESTIONS TO EITHER THE COURT OR THE CLERK’S OFFICE. Any questions you have about matters in this Notice should be directed by telephone or in writing to Plaintiffs’ Counsel and Defendants’ Counsel at the addresses set forth above.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103793144/en/

For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

Source: Twist Bioscience Corporation